United Kingdom · Question · Written question
UIN 4513
Colestyramine
Original
Introduced
29 May 2026
Last action
16 June 2026 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
16 June 2026
Summary
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the reported withdrawal of the original formulation of Questran from the UK market on patients with bile acid malabsorption.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
29 May 2026
Written question
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the reported withdrawal of the original formulation of Questran from the UK market on patients with bile acid malabsorption.
Source: Commons
16 June 2026
Answer
The Department is aware of the discontinuation of the original formulation of Questran (colestyramine 4g oral powder) sachets. Decisions to discontinue medicines are commercial decisions for manufacturers, and the Department does not have powers to requir...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2026-05-29/4513
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1909591
- uk · wq-1909591 · source updated 16 June 2026